Other News

Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update

MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the second quarter of 2021 and provided a business update. “We are entering an exciting period […]

Occlutech granted important conditional FDA approval for PFO Study (OCCLUFLEX) in the U.S.

SCHAFFHAUSEN, Switzerland, Aug. 16, 2021 /PRNewswire/ — Occlutech Holding AG (“Occlutech”), one of the world´s leading providers of minimally invasive structural heart disease devices, announces the conditional U.S. Food and Drug Administration (“FDA”) approval of its Investigational Device Exemption (“IDE”) application to conduct a pivotal study, OCCLUFLEX, comparing Patent Foramen Ovale (“PFO”) closure by […]

ABBOTT’S AMPLATZER™ AMULET™ DEVICE APPROVED BY FDA TO TREAT PEOPLE WITH ATRIAL FIBRILLATION AT RISK OF STROKE

– Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn’t needed following implantation – The device helps to prevent blood clots from forming and leaving the LAA, reducing the risk of stroke in patients with […]

Ultromics Raises $33M in Series B Funding to Help Transform Cardiac Disease Treatment

Led by Blue Venture Fund, new funding will accelerate Ultromics’ use of AI-enabled echocardiograms to improve patient outcomes OXFORD, England, Aug. 16, 2021 /PRNewswire/ — Ultromics, a leader in AI enabled cardiovascular imaging solutions, announced today that it has raised $33 million in a Series B funding round. The round was led by the […]

NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results

BOSTON, Aug. 16, 2021 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2021. Management Commentary “During the second quarter, we continued to advance the Phase 2/3 clinical trial […]

Eko Brings Cardiopulmonary Focus to the Frontline of Care With the Next Generation DUO

The pocket-sized cardiac examination system helps clinicians of all types detect heart disease earlier OAKLAND, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) — Eko, a cardiopulmonary digital health company, today announced the launch of the next generation Eko DUO. DUO is the first FDA-cleared cardiac assessment tool that functions as an electrocardiogram (ECG) […]

JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial

IRVINE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced FDA approval for the company to initiate its Investigational Device Exemption (IDE) PMA clinical trial for the Trilogy™ Heart Valve System for severe symptomatic, high-surgical risk […]

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc.   (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced its financial results for the quarter ended June 30, 2021, and recent events. “It has […]

LivaNova Announces Early Retirement of $450 Million Term Loan and Executes $125 Million Revolving Credit Facility

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the early retirement of its $450 million five-year senior secured term loan (the Term Loan). To retire the Term Loan, LivaNova repaid the $450 million principal amount outstanding, plus accrued interest and an approximately $35.6 million make-whole […]